At September 30, 2025, Edesa had cash and cash equivalents of $10.8 million and working capital of $10.4 million. Subsequent to the fiscal year end, the company received $3.4 million in net proceeds, ...
Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...
A 2025 report from a bipartisan, congressionally chartered commission warns that China is closing in on a win, and the United ...
In the northwest corner of Sioux Falls, an 80-acre campus opened its first building this year dedicated entirely to expanding ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...
Commentary: Biotechnology lets scientists engineer natural ingredients into products, often more sustainably than if they were farmed. Here's what to know. Deenie is a CNET Perspectives contributor ...
In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...
Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...
A hand holds up a tamper-safe orange bottle filled with oblong white pills against a red-tinted background of Chinese yuan. As China’s biopharmaceutical industry churns out more innovative molecules, ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
‘Disheartening? Yes. Surprising? No.’ Report on the future of biotech in Mass. gives a grim outlook.
The industry group MassBio released its annual temperature check on the state’s biotech industry Tuesday, and the results are grim. Both public and private funding have plummeted as federal policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback